Cargando…

Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats

BACKGROUND: Glucagon-like peptide-2 (GLP-2) enhances intestinal repair and attenuates inflammation in preclinical inflammatory bowel disease (IBD) models, making GLP-2 analogues attractive candidates for IBD therapy. Glepaglutide is a long-acting GLP-2 receptor agonist in clinical development for tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skarbaliene, Jolanta, Mathiesen, Jesper Mosolff, Larsen, Bjarne Due, Thorkildsen, Christian, Petersen, Yvette Miata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029296/ https://www.ncbi.nlm.nih.gov/pubmed/36944922 http://dx.doi.org/10.1186/s12876-023-02716-4

Ejemplares similares

Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects
por: Agersnap, Mikkel Askjær, et al.
Publicado: (2022)

Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment
por: Agersnap, Mikkel Askjær, et al.
Publicado: (2023)

Effects of glepaglutide, a long‐acting glucagon‐like peptide‐2 analog, on intestinal morphology and perfusion in patients with short bowel syndrome: Findings from a randomized phase 2 trial
por: Naimi, Rahim M., et al.
Publicado: (2022)

Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial
por: Naimi, Rahim Mohammad, et al.
Publicado: (2019)

Correction to: Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment
por: Agersnap, Mikkel Askjær, et al.
Publicado: (2023)

Hospital Physicians' Influence on Gastrointestinal Protection during Treatment with Non-Steroidal Anti-Inflammatory Drugs and Acetylsalicylic Acid and the Impact on Prescribing in Primary Care
por: Larsen, Michael Due, et al.
Publicado: (2013)

Anti-inflammatory and atheroprotective properties of glucagon
por: Osaka, Naoya, et al.
Publicado: (2020)

Amelioration of inflammatory myopathies by glucagon‐like peptide‐1 receptor agonist via suppressing muscle fibre necroptosis
por: Kamiya, Mari, et al.
Publicado: (2022)

Mucosal Lipocalin 2 Has Pro-Inflammatory and Iron-Sequestering Effects in Response to Bacterial Enterobactin
por: Bachman, Michael A., et al.
Publicado: (2009)

Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis
por: Meurot, C., et al.
Publicado: (2022)

The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)

Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes.
por: Lu, Nan, et al.
Publicado: (2015)

Antagonism of the prostaglandin D(2 )receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation
por: Uller, Lena, et al.
Publicado: (2007)

Mucosal-Associated Invariant T Cells in Regenerative Medicine
por: Wakao, Hiroshi, et al.
Publicado: (2017)

Effects of exendin-4, a glucagon like peptide-1 receptor agonist, on neutrophil count and inflammatory cytokines in a rat model of endotoxemia
por: Yanay, Ofer, et al.
Publicado: (2015)

Organoid-based regenerative medicine for inflammatory bowel disease
por: Okamoto, Ryuichi, et al.
Publicado: (2020)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Conformation Transition of Intracellular Part of Glucagon Receptor in Complex With Agonist Glucagon by Conventional and Accelerated Molecular Dynamics Simulations
por: Bai, Qifeng, et al.
Publicado: (2019)

Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons
por: Pontiroli, Antonio E., et al.
Publicado: (2022)

Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls
por: Simonsen, Lotte, et al.
Publicado: (2022)

The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease
por: Larsen, Lone, et al.
Publicado: (2016)

Anti-inflammatory treatment induced regenerative oligodendrogenesis in parkinsonian mice
por: Worlitzer, Maik MA, et al.
Publicado: (2012)

Mucosal Inflammatory Response to Salmonella typhimurium Infection
por: Patel, Samir, et al.
Publicado: (2014)

Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
por: Mehdi, Syed Faizan, et al.
Publicado: (2023)

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists
por: Zhang, Yu-Juan, et al.
Publicado: (2013)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
por: Delgado, A., et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
por: Wojtara, Magda, et al.
Publicado: (2023)

Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in Stroke
por: Kim, Soojin, et al.
Publicado: (2017)

Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
por: Eriksson, Olof, et al.
Publicado: (2020)

Dominant Fecal Microbiota in Newly Diagnosed Untreated Inflammatory Bowel Disease Patients
por: Thorkildsen, Lill Therese, et al.
Publicado: (2013)

Tissue communication in regenerative inflammatory signaling: lessons from the fly gut
por: Kux, Kristina, et al.
Publicado: (2014)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Pulmonary-intestinal cross-talk in mucosal inflammatory disease
por: Keely, Simon, et al.
Publicado: (2011)

Glucagon is associated with NAFLD inflammatory progression in type 2 diabetes, not with NAFLD fibrotic progression
por: Wang, Yuying, et al.
Publicado: (2021)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_osss8cbvhf9418hit59snj92cn